Discover how the next wave of biosimilars can enhance affordability and access for your members and sustainability for your specialty spend.

The Next Wave of Biosimilars What It Means for Employers, Health Plans and Their Members WHY YOU SHOULD WATCH The landscape looks a lot different today than when Humira® biosimilars launched in 2023. How can payers, patients and plan sponsors benefit from this expanding market for alternatives to other biologics?   Tune into to this short […]